R&D channel feed – Endpoints News

R&D channel feed

Axovant's lead Alzheimer's drug flops in PhIII, ending an unlikely quest

8 years ago

Genocea shelves its lead drug, slashes staff and switches focus to trendy neoantigens

8 years ago

ProQR spotlights the most encouraging results from a mixed snapshot of efficacy for cystic fibrosis

8 years ago

J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK

8 years ago

Puretech’s Gelesis flunks the FDA’s key measure of success for weight loss treatments

8 years ago

Visualize: What would these 11 biotech companies look like without immigrants?

8 years ago

Two years on, Allergan’s $1.7B NASH drug still looks weak — at best

8 years ago

AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs

8 years ago

Versartis shares hammered by a PhIII flop as growth hormone flunks key test

8 years ago

Nestle plans to ax hundreds of R&D staffers, shutter big dermatology campus

8 years ago

Want to start fixing the gender diversity problem in your biotech company? Put down the silver bullet

8 years ago

Alnylam achieves breakthrough RNAi success as PhIII patisiran study hits all goals, shares soar

8 years ago

AbbVie and Roche tout a positive PhIII combo study of Venclexta, Rituxan in CLL — ahead of FDA pitch

8 years ago

Shares rocket up as Nabriva Therapeutics touts a PhIII win for antibiotic

8 years ago

Closing in on another mega-raise, UK biotech star Immunocore grabs $40M investment from Gates Foundation

8 years ago

Kerrisdale 2-0 this week: Bavarian Nordic's cancer vaccine is a bust in PhIII

8 years ago

New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi

8 years ago

Mustang ties the knot with Fred Hutch on next-gen CAR-T for lymphoma

8 years ago

AstraZeneca and Moderna take a big, early step forward in their quest to prove mRNA works in humans

8 years ago

Great data! Huge potential! (Too bad it failed the primary endpoint)

8 years ago

GSK lines up a shot at a blockbuster market as new CEO prepares to tackle Merck rival head on

8 years ago

Otonomy brings out the ax after a catastrophic PhIII failure

8 years ago

As rivals look to carve up its blockbuster revenue, Novartis’ Cosentyx registers remarkably consistent effect for psoriasis

8 years ago

Amicus scraps a top rare disease drug after it flunks a pivotal test — and shares spike

8 years ago

First page Previous page 288 289 290291292 293 294 Next page Last page